The public offering will dilute existing shareholders. Investors should monitor for the prospectus filing to assess offering size, price, and use of proceeds. The suspension of the ATM program suggests a shift to a fixed-price offering, potentially indicating urgency in capital raising.
Price Chart
Executive Summary
Allogene Therapeutics announced a proposed underwritten public offering of its common stock and suspended its existing at-the-market (ATM) sales agreement. The company will not sell shares under the prior ATM program until a new prospectus is filed.
Key Facts
- Allogene Therapeutics announced a proposed underwritten public offering of common stock on April 13, 2026.
- The company suspended its existing at-the-market (ATM) sales agreement dated November 5, 2019, as amended.
- No sales will occur under the prior ATM agreement unless and until a new prospectus or prospectus supplement is filed with the SEC.
Financial Impact
Dilutive equity offering expected; size not disclosed. Suspends prior ATM program under Sales Agreement dated Nov 5, 2019.
Risk Factors
- Equity dilution from the offering will reduce per-share value.
- Proceeds may not be deployed efficiently, given Allogene's pre-revenue biotech profile.
- Market reaction could be negative if offering terms are perceived as unfavorable.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-152866 |
| Document: 0001193125-26-152866-index-headers.html | 0001193125-26-152866 |
| Document: 0001193125-26-152866-index.html | 0001193125-26-152866 |
| Document: 0001193125-26-152866.txt | 0001193125-26-152866 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 27, 2026 today | SC 13G/A | $1.21 | awaiting T+1 | — | $1.23 (+1.65%) |
Oct 21, 2026 6d ago | 144 | $1.25 $1.25 | · 0.00% | ▲ +0.52% | $1.23 (−1.60%) |
Sep 2, 2026 7w ago | 8-K | $1.98 $1.98 | · 0.00% | ▼ −1.05% | $1.23 (−37.88%) |
Aug 21, 2026 9w ago | 144 | $2.03 $2.17 | ▲ +6.90% | ▲ +6.58% | $1.23 (−39.41%) |
Aug 21, 2026 9w ago | EFFECT | $2.09 $2.03 | ▲ +2.87% | ▲ +2.58% | $1.23 (+41.15%) |
Aug 6, 2026 11w ago | Institutional Cluster | $1.97 $2.01 | ▲ +2.03% | ▲ +1.42% | $1.23 (−37.56%) |
Jun 22, 2026 18w ago | 8-K | $2.07 $2.05 | ▲ +0.97% | ▲ +0.92% | $1.23 (+40.58%) |
Jun 22, 2026 18w ago | 424B5 | $2.07 $2.05 | ▲ +0.97% | ▲ +0.92% | $1.23 (+40.58%) |
May 28, 2026 21w ago | DEFA14A | $2.17 $2.15 | ▼ −0.92% | ▼ −1.18% | $1.23 (−43.32%) |
May 28, 2026 21w ago | 8-K | $2.17 $2.15 | ▼ −0.92% | ▼ −1.18% | $1.23 (−43.32%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers